Amoy Diagnostics Future Growth
Future criteria checks 3/6
Amoy Diagnostics is forecast to grow earnings and revenue by 21.1% and 16.6% per annum respectively. EPS is expected to grow by 20.7% per annum. Return on equity is forecast to be 18.3% in 3 years.
Key information
21.1%
Earnings growth rate
20.7%
EPS growth rate
| Biotechs earnings growth | 51.2% |
| Revenue growth rate | 16.6% |
| Future return on equity | 18.3% |
| Analyst coverage | Good |
| Last updated | 29 Apr 2025 |
Recent future growth updates
Recent updates
Is Amoy Diagnostics (SZSE:300685) A Risky Investment?
Mar 21
Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Low P/E No Reason For Excitement
Jan 27Estimating The Fair Value Of Amoy Diagnostics Co., Ltd. (SZSE:300685)
Jan 07Amoy Diagnostics (SZSE:300685) Has A Rock Solid Balance Sheet
Dec 19Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Earnings Haven't Escaped The Attention Of Investors
Sep 18Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?
Aug 23Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's
May 27Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%
Apr 24Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt
Apr 18What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You
Mar 02Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?
Mar 01Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 1,777 | 485 | N/A | 415 | 5 |
| 12/31/2026 | 1,657 | 424 | 351 | 360 | 10 |
| 12/31/2025 | 1,309 | 335 | 303 | 264 | 6 |
| 12/31/2024 | 1,109 | 255 | 302 | 342 | N/A |
| 9/30/2024 | 1,184 | 315 | 289 | 324 | N/A |
| 6/30/2024 | 1,128 | 279 | 262 | 295 | N/A |
| 3/31/2024 | 1,082 | 268 | 274 | 312 | N/A |
| 12/31/2023 | 1,044 | 261 | 254 | 299 | N/A |
| 9/30/2023 | 951 | 213 | 222 | 269 | N/A |
| 6/30/2023 | 908 | 301 | 164 | 222 | N/A |
| 3/31/2023 | 831 | 267 | 108 | 189 | N/A |
| 1/1/2023 | 842 | 264 | 71 | 149 | N/A |
| 9/30/2022 | 871 | 287 | 75 | 140 | N/A |
| 6/30/2022 | 911 | 218 | 81 | 146 | N/A |
| 3/31/2022 | 949 | 250 | 88 | 134 | N/A |
| 1/1/2022 | 917 | 240 | 94 | 168 | N/A |
| 9/30/2021 | 890 | 231 | 107 | 196 | N/A |
| 6/30/2021 | 844 | 211 | 125 | 224 | N/A |
| 3/31/2021 | 811 | 198 | 143 | 235 | N/A |
| 12/31/2020 | 728 | 180 | 163 | 221 | N/A |
| 9/30/2020 | 650 | 153 | 114 | 167 | N/A |
| 6/30/2020 | 595 | 138 | 126 | 159 | N/A |
| 3/31/2020 | 550 | 129 | 143 | 170 | N/A |
| 12/31/2019 | 578 | 135 | 128 | 152 | N/A |
| 9/30/2019 | 541 | 140 | 126 | 153 | N/A |
| 6/30/2019 | 502 | 135 | 87 | 120 | N/A |
| 3/31/2019 | 469 | 134 | 66 | 104 | N/A |
| 12/31/2018 | 439 | 127 | 54 | 93 | N/A |
| 9/30/2018 | 398 | 122 | N/A | 108 | N/A |
| 6/30/2018 | 384 | 120 | N/A | 114 | N/A |
| 3/31/2018 | 357 | 103 | N/A | 96 | N/A |
| 12/31/2017 | 330 | 94 | N/A | 92 | N/A |
| 9/30/2017 | 315 | 82 | N/A | 70 | N/A |
| 6/30/2017 | 288 | 78 | N/A | 49 | N/A |
| 3/31/2017 | 258 | 67 | N/A | 40 | N/A |
| 12/31/2016 | 253 | 67 | N/A | 32 | N/A |
| 6/30/2016 | 220 | 42 | N/A | 24 | N/A |
| 3/31/2016 | 198 | 32 | N/A | 22 | N/A |
| 12/31/2015 | 177 | 21 | N/A | 19 | N/A |
| 12/31/2014 | 107 | 19 | N/A | 16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300685's forecast earnings growth (21.1% per year) is above the savings rate (2.7%).
Earnings vs Market: 300685's earnings (21.1% per year) are forecast to grow slower than the CN market (23.9% per year).
High Growth Earnings: 300685's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300685's revenue (16.6% per year) is forecast to grow faster than the CN market (12.6% per year).
High Growth Revenue: 300685's revenue (16.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300685's Return on Equity is forecast to be low in 3 years time (18.3%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 21:49 |
| End of Day Share Price | 2025/05/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amoy Diagnostics Co., Ltd. is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yolanda Yin | China Galaxy International Securities (Hong Kong) |
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Ziyu He | China International Capital Corporation Limited |